Institution statistics

F. HOFFMANN-LA ROCHE AG - Switzerland 

Ranking results:

Past rankings:
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:700-800
Total Project Funding:700-800
Total Project Funding per Partner:700-800
Total Number of Projects:68
Networking Rank (Reputation):700-800
Networking Rank (Reputation):700-800
Partner Constancy:46
Project Leadership Index:75
Diversity Index:41
Ranking timeline:

European project participation (2000-01-01 - 2019-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 30
As coordinator: 0
As participant: 30
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2019 0 55.472.314 0 3
2018 0 130.275.644 0 4
2017 0 39.890.523 0 4
2016 0 54.639.549 0 5
2015 0 5.972.496 0 1
2014 0 5.998.346 124.247 1
2013 0 15.918.137 762.895 2
2012 0 17.316.160 201.181 3
2011 0 3.496.556 253.634 1
2010 0 1.762.399 141.847 1
2009 0 2.989.845 427.121 1
2008 0 8.040.110 736.992 3
2005 0 11.998.527 285.679 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
JANSSEN PHARMACEUTICA NV12
NOVARTIS PHARMA12
ELI LILLY AND COMPANY LIMITED9
UNIVERSITY COLLEGE LONDON9
PFIZER LIMITED7
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT7
STICHTING KATHOLIEKE UNIVERSITEIT7
CHARITE UNIVERSITAETSMEDIZIN BERLIN6
THE UNIVERSITY OF EDINBURGH6
BAYER AKTIENGESELLSCHAFT5
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE5
KING'S COLLEGE LONDON5
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL5
ARTTIC4
ASTRAZENECA AB4
EBERHARD KARLS UNIVERSITAET TUEBINGEN4
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM4
H LUNDBECK AS4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER4
KAROLINSKA INSTITUTET4
RIJKSUNIVERSITEIT GRONINGEN4
TAKEDA DEVELOPMENT CENTRE EUROPE4
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE4
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD4
UCB BIOPHARMA SPRL4
UNIVERSITEIT MAASTRICHT4
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN4
UNIVERSITY OF NEWCASTLE UPON TYNE4
ACADEMISCH ZIEKENHUIS LEIDEN3
ALZHEIMER EUROPE3
BOEHRINGER INGELHEIM INTERNATIONALGMBH3
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
FUNDACIO SANT JOAN DE DEU3
KAROLINSKA INSTITUTE3
REGION HOVEDSTADEN3
SANOFIAVENTIS DEUTSCHLAND3
STICHTING BURO ECNP3
STICHTING VU3
SYNAPTOLOGICS BV3
UNIVERSITAETSKLINIKUM BONN3
UNIVERSITAIR MEDISCH CENTRUM UTRECHT3
UNIVERSITAT BASEL3
UNIVERSITEIT GENT3
UNIVERSITEIT LEIDEN3
ABBVIE INC2
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
CONCENTRIS RESEARCH MANAGEMENT2
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED MP2
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK2
FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E V2
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV2
FUNDACIO CENTRE DE REGULACIO GENOMICA2
FUNDACION HOSPITAL LA FE2
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD2
GENEDATA2
GOETEBORGS UNIVERSITET2
INSPHERO2
INSTITUT GUSTAVE ROUSSY2
INSTITUT PASTEUR2
KATHOLIEKE UNIVERSITEIT LEUVEN2
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN2
KUNGLIGA TEKNISKA HOEGSKOLAN2
LHASA LIMITED2
LIFE AND BRAIN2
LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN2
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV2
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV2
MEDIZINISCHE HOCHSCHULE HANNOVER2
MEDIZINISCHE UNIVERSITAET WIEN2
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN2
MERCK SHARP & DOHME CORP2
MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST2
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE2
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO2
NOLDUS INFORMATION TECHNOLOGY BV2
NOVO NORDISK2
NV ORGANON2
OPTIBRIUM LIMITED2
ORION OYJ2
SERVICIO ANDALUZ DE SALUD2
SERVICIO MADRILENO DE SALUD2
STICHTING VUMC2
TECHNISCHE UNIVERSITAET DRESDEN2
THE PROVOST FELLOWS FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN2
THE UNIVERSITY OF LIVERPOOL2
TP212
UNIVERSIDAD DE SALAMANCA2
UNIVERSIDAD POMPEU FABRA2
UNIVERSITAET BERN2
UNIVERSITAET KONSTANZ2
UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTUNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS2
UNIVERSITAT WIEN2
UNIVERSITAT ZURICH2
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK2
UNIVERSITY OF COPENHAGEN2
Constancy:

Total number of partners:643

Partner loyalty:
Frequent Partner: (> 2 projects): 215
Rare Partner: 428

Frequent / Rare Partner Ratio: 0.5

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES10
INDUSTRY AND TECHNOLOGY4
RTD HORIZONTAL TOPICS2
SOCIAL AND ECONOMIC CONCERNS2

Project overview:

Start dateProjectacronymrolefundingpartners
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19269
2019-03-01Efficiently Networking European Neurodegeneration Research NEURONETparticipant1.199.1259
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2018-10-01European Training Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent Inherited Blinding Disorder StarTparticipant3.776.71415
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00043
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00019
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-01-01Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders COSYNparticipant5.925.00014
2016-01-01An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century EU-ToxRiskparticipant27.798.29939
2015-05-01Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways EYE-RISKparticipant5.972.49612
2014-02-01Translating neuroimaging findings from research into clinical practice PSYSCANparticipant5.998.34615
2013-10-01Deciphering inter- and intracellular signalling in schizophrenia IN-SENSparticipant3.918.13813
2013-10-01Hepatic and Cardiac Toxicity Systems modelling HECATOSparticipant11.999.99914
2012-05-01New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier TRANS-INTparticipant8.000.00017
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512
2012-02-01Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies SALUSparticipant3.325.96510
2011-04-01Biomedical engineering for cancer and brain disease diagnosis and therapy development EngCaBraparticipant3.496.5569
2010-07-01Histopathologic and Mechanistic Assessment of Angiogenesis Inhibitor Related Toxicities: A Cross-Sectoral, Multi-disciplinary Approach ANGIOTOXparticipant1.762.39910
2009-11-01Blood-brain barrier junctions as targets for paracellular drug delivery to the brain JUSTBRAINparticipant2.989.8457
2008-09-01Functional assays for membrane protein on nanostructured supports ASMENAparticipant3.940.09814
2008-06-01Computational prediction of drug cardiac toxicity PREDICTparticipant4.100.0009
2008-04-01Embryonic stem cell-based novel alternative testing strategies ESNATSparticipant1232
2005-10-01Innovative medicines for europe INNOMEDparticipant11.998.52742
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum